Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded market
Briefly

"Today, we cannot get the 0.25 milligram dose of Wegovy or Zepbound in 10mg, so it really depends on the dose and the day," said Dr. Eduardo Grunvald, an obesity medicine physician at University of California, San Diego.
Lilly attributed the shortfall to a logistical issue as it worked to overcome a shortage of its two drugs, which share the same active ingredient.
Four of the doctors told Reuters that patients are also still finding it hard to get various doses at times and are shopping around pharmacies to find supply.
Those frustrations, along with the medicines' high cost, are pushing patients to cheaper compounded versions sold online, doctors, pharmacy officials and Wall Street analysts said.
Read at Fast Company
[
|
]